Lorundrostat (MT-4129) is a highly selective inhibitor of CYP11B2 (aldosterone synthase), with inhibition constant (Ki) values of 1.27 nM for hCYP11B2 and 475 nM for hCYP11B1. It demonstrates potential as a safe and effective treatment for aldosterone-dependent uncontrolled hypertension, including cases of treatment-resistant hypertension.

Lorundrostat (MT-4129) is a highly selective inhibitor of CYP11B2 (aldosterone synthase), with inhibition constant (Ki) values of 1.27 nM for hCYP11B2 and 475 nM for hCYP11B1. It demonstrates potential as a safe and effective treatment for aldosterone-dependent uncontrolled hypertension, including cases of treatment-resistant hypertension.

Lorundrostat (MT-4129) is a highly selective inhibitor of CYP11B2 (aldosterone synthase), with inhibition constant (Ki) values of 1.27 nM for hCYP11B2 and 475 nM for hCYP11B1. It demonstrates potential as a safe and effective treatment for aldosterone-dependent uncontrolled hypertension, including cases of treatment-resistant hypertension.

Tersolisib (STX-478) is a highly potent, mutant-selective, allosteric inhibitor of PI3Kα, that selectively targets prevalent mutant forms of PI3Kα. It demonstrates strong efficacy against common PI3Kα helical- and kinase-domain mutations, including the H1047R variant, with an IC50 value of 9.4 nmol/L. STX-478 exhibits 14-fold greater selectivity for mutant PI3Kα over the wild-type form. It spares […]

Tersolisib (STX-478) is a highly potent, mutant-selective, allosteric inhibitor of PI3Kα, that selectively targets prevalent mutant forms of PI3Kα. It demonstrates strong efficacy against common PI3Kα helical- and kinase-domain mutations, including the H1047R variant, with an IC50 value of 9.4 nmol/L. STX-478 exhibits 14-fold greater selectivity for mutant PI3Kα over the wild-type form. It spares […]

Tersolisib (STX-478) is a highly potent, mutant-selective, allosteric inhibitor of PI3Kα, that selectively targets prevalent mutant forms of PI3Kα. It demonstrates strong efficacy against common PI3Kα helical- and kinase-domain mutations, including the H1047R variant, with an IC50 value of 9.4 nmol/L. STX-478 exhibits 14-fold greater selectivity for mutant PI3Kα over the wild-type form. It spares […]

Tersolisib (STX-478) is a highly potent, mutant-selective, allosteric inhibitor of PI3Kα, that selectively targets prevalent mutant forms of PI3Kα. It demonstrates strong efficacy against common PI3Kα helical- and kinase-domain mutations, including the H1047R variant, with an IC50 value of 9.4 nmol/L. STX-478 exhibits 14-fold greater selectivity for mutant PI3Kα over the wild-type form. It spares […]

Resigratinib (KIN-3248) is a potent, kinome selective, irreversible, orally bioavailable, small-molecule inhibitor of pan-FGFR. It exhibits dose-dependent tumor inhibition in FGFR driven cholangiocarcinoma, gastric, and bladder cancer xenograft models.

Resigratinib (KIN-3248) is a potent, kinome selective, irreversible, orally bioavailable, small-molecule inhibitor of pan-FGFR. It exhibits dose-dependent tumor inhibition in FGFR driven cholangiocarcinoma, gastric, and bladder cancer xenograft models.

Resigratinib (KIN-3248) is a potent, kinome selective, irreversible, orally bioavailable, small-molecule inhibitor of pan-FGFR. It exhibits dose-dependent tumor inhibition in FGFR driven cholangiocarcinoma, gastric, and bladder cancer xenograft models.